Polyclonal Antibody to Tissue Factor (TF) Oryctolagus cuniculus (Rabbit) Polyclonal antibody

CD142; FIII; F3; TFA; Thromboplastin; Coagulation Factor III

Add to Cart Distributors
Overview
Properties
  • SourcePolyclonal antibody preparation, Host Guinea pig
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelAPC
  • Immunogen RPA524Rb01-Recombinant Tissue Factor (TF)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 500µg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Polyclonal Antibody to Tissue Factor (TF) Packages (Simulation)
  • Polyclonal Antibody to Tissue Factor (TF) Packages (Simulation)
  • Polyclonal Antibody to Tissue Factor (TF) DAB staining on IHC-P; Samples: Rabbit Pancreas Tissue; Primary Ab: 20μg/ml Cavia Anti-Rabbit TF Antibody Second Ab: 2µg/mL HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody (Catalog: SAA544Gu09)
  • PAA524Rb51.jpg Figure. Western Blot; Sample: Recombinant TF, Rabbit.
  • Polyclonal Antibody to Tissue Factor (TF) Western Blot; Sample: Lane1: Rabbit Thymus lysate; Lane2: Rabbit Testis lysate; Lane3: Rabbit Lung lysate
    Primary Ab: 2µg/ml Cavia Anti-Rabbit TF Antibody
    Second Ab: 0.2µg/mL HRP-Linked Rabbit Anti-Cavia IgG Polyclonal Antibody
    (Catalog: SAA544Gu09)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a cavia polyclonal antibody raised against TF. It has been selected for its ability to recognize TF in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Calcitonin gene-related peptide-mediated antihypertensive and anti-platelet effects by rutaecarpine in spontaneously hypertensive ratsPubMed: 18625276
  • Increased plasma level of asymmetric dimethylarginine in hypertensive rats facilitates platelet aggregation: role of plasma tissue factorNrcresearchpress: y10-115
  • Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in ratsPubmed: 23538027
  • Endothelial gene expression and molecular changes in response to radiosurgery in in vitro and in vivo models of cerebral arteriovenous malformationsPubmed: 24199192
  • Sphingolipid Pathway Regulates Innate Immune Responses at the Fetomaternal Interface during PregnancyPubmed:25505239
  • Thrombosis in Hemodialysis Patients; Their Association with Tissue Factor and Tissue Factor Pathway InhibitorPubMed: 20011089
  • Noble-Collip Drum Trauma Induces Disseminated Intravascular Coagulation But Not Acute Coagulopathy of Trauma-ShockPubMed: 25423126
  • Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testingPubMed: 26243277
  • Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptorsPubMed: 25546502
  • The effects of polysaccharides from the root of Angelica sinensis on tumor growth and iron metabolism in H22-bearing micePubmed:26757699
  • Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injurypubmed:29202212
  • Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndromePubmed: 29202212
  • Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in ratsPubmed: 31755229
  • Amelioration of Coagulation Disorders and Inflammation by Hydrogen-Rich Solution Reduces Intestinal Ischemia/Reperfusion Injury in Rats through NF-κB …Pubmed: 32587471
  • Effect of Glucocorticoid Administration in Intravenous Pulses on Selected Parameters of the Coagulation SystemPubmed:35685509

Recommend products